Steven E. Benner, MD, Senior Vice President and Global Therapeutic Head for Oncology at Astellas Oncology discusses whether or not there is a phase 3 trial in the works for the use of gilteritinib for treatment of relapsed/refractory acute myeloid leukemia. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Abstract 7003: Deep molecular response to gilteritinib to improve survival in FLT3 mutation-positive relapsed/refractory acute myeloid leukemia